VMTHF (Venus Medtech (Hangzhou)) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VMTHF Venus Medtech (Hangzhou) Inc VMTHF
52 GF Score
Price $0.42
GF Value $1.27
! 4 Warning Signs
View Full Analysis

What is Venus Medtech (Hangzhou) FFO?

FFO (Funds from operations) only applies to REITs.

VMTHF
52GF Score
Venus Medtech (Hangzhou) Inc VMTHF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued. The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.

Key valuation signals for VMTHF:

  • FFO:
  • GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Venus Medtech (Hangzhou) Business Description

Other Exchanges 02500:Hong Kong
Address No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score

Get the complete analysis for VMTHF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price
$1.27
GF Value